Huiqin Yang

Search results

• 2010

  Bevacizumab in combination with a taxane for the first-line treatment of HER2-negative metastatic breast cancer: a single technology appraisal.

  CRD and CHE Technology Assessment Group, Rodgers, M., O Soares, M., Epstein, D., Yang, H. & Eastwood, A. J., 2010, Centre for Reviews and Dissemination/ Centre for Health Economics.

  Research output: Book/Report › Other report